Hypercalcemia refers to the condition where too much calcium enters the extracellular fluid or when there is insufficient calcium excretion from the kidneys. The cases of hypercalcemia are mainly caused by malignancy or hyperparathyroidism.Hypercalcemia is an outcome of overactive parathyroid glands. These four tiny glands are located near thyroid gland and each of them are about the size of a rice grain. The causes of hypercalcemia are some medications, and excessive use of calcium and vitamin D supplements.The global hypercalcemia treatment market is expected to benefit from the growing incidence of chronic conditions that cause spasticity and spasms. Some of these conditions include multiple sclerosis and cerebral palsy. This has driven vendors to conduct R&D, thereby driving the market growth.

PART 01: Executive summary 6

PART 02: Scope of the report 17

PART 03: Research Methodology 22

PART 04: Introduction 25

Key market highlights 25

PART 05: An overview of Hypercalcemia 26

PART 06: Pipeline Analysis 27

PART 07: Market landscape 28

Market overview 28

Five forces analysis 31

PART 08: Market segmentation by product type 32

Bisphosphonates 32

Glucocorticoids 33

Calcimimetic agents 34

Others 35

PART 09: Market segmentation by geography 36

Hypercalcemia treatment market in Americas 37

Hypercalcemia treatment market in EMEA 39

Hypercalcemia treatment market in APAC 41

PART 10: Decision framework 43

PART 11: Drivers and challenges 45

Market drivers 46

Impact of drivers on key customer segments 49

Market challenges 50

Impact of challenges on key customer segments 53

PART 12: Market trends 54

Combination therapy 54

Increase in outsourcing 54

Growing focus on emerging economies 54

PART 13: Vendor landscape 55

Competitive scenario 55

PART 14: Key vendor analysis 58

AbbVie 58

Amgen 60

Merck 63

Novartis 65

OPKO Health 67

Other prominent vendors 69

PART 15: Appendix 71

List of abbreviations 71

PART 16: Explore Technavio 72

Table of contents

EMISPDF